Lentinan Market Size, Share, Growth, and Industry Analysis, By Type (Food Grade, Pharmaceutical Grade), By Application (Food Additive, Health Product Field, Anti-Cancer Drug), Regional Insights and Forecast to 2035

Lentinan Market Overview

Lentinan Market size is projected at USD 12.79 million in 2026 and is expected to hit USD 22.7 million by 2035 with a CAGR of 6.58%.

The lentinan market is expanding steadily due to increasing demand for mushroom-derived bioactive compounds in pharmaceuticals, nutraceuticals, and functional foods. Lentinan, a beta-glucan extracted primarily from shiitake mushrooms, is widely used for immune modulation and adjunct cancer therapy. Global shiitake mushroom production exceeded 11 million metric tons during 2024, with China contributing approximately 82% of total supply. Pharmaceutical-grade lentinan accounted for nearly 58% of global consumption because of rising oncology-related applications. More than 46% of nutraceutical manufacturers incorporated beta-glucan ingredients into immune-support supplements during 2024. Functional food applications using lentinan increased by 23% because consumers increasingly preferred plant-based immunity ingredients and natural polysaccharides.

The United States lentinan market demonstrated strong growth due to rising consumption of immune-health supplements and mushroom-based nutraceuticals. More than 61% of dietary supplement users in the United States purchased immunity-focused products during 2024. Shiitake mushroom imports exceeded 82,000 metric tons, supporting domestic lentinan extraction and supplement production. Pharmaceutical applications represented approximately 41% of U.S. lentinan demand because adjunct oncology therapies gained wider clinical attention. Functional food products containing mushroom beta-glucans increased by 19% across retail shelves. More than 3,400 nutraceutical companies in the United States introduced mushroom-derived capsules, powders, and tablets containing lentinan for immune support and wellness applications.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Immune-health supplement consumption increased by 43%, oncology-related nutraceutical demand rose by 31%, and functional food applications expanded by 27%, significantly boosting lentinan market utilization worldwide.
• Major Market Restraint: Nearly 34% of manufacturers faced raw mushroom supply instability, while 22% of consumers reported limited awareness regarding lentinan therapeutic benefits across developing economies.
• Emerging Trends: Organic mushroom extract demand increased by 29%, beta-glucan supplement adoption rose by 37%, and plant-based immune products accounted for 46% of nutraceutical product launches globally.
• Regional Leadership: Asia-Pacific represented approximately 68% of global lentinan production, while China contributed nearly 82% of shiitake mushroom cultivation and extraction processing activities worldwide.
• Competitive Landscape: The top five manufacturers controlled nearly 51% of global lentinan supply, while pharmaceutical-grade production facilities expanded by 24% during 2024 across Asia and North America.
• Market Segmentation: Pharmaceutical-grade lentinan represented 58% of market demand, anti-cancer drug applications accounted for 39%, and health product formulations maintained approximately 34% global consumption share.
• Recent Development: Between 2023 and 2025, encapsulated beta-glucan formulations increased by 26%, immune-support product launches expanded by 31%, and purified lentinan extraction efficiency improved by 18%.

Lentinan Market Latest Trends

The lentinan market is witnessing rapid expansion because consumers increasingly prefer natural immune-enhancing ingredients and mushroom-derived nutraceuticals. Beta-glucan supplement launches increased by 37% during 2024, while mushroom-based capsule sales expanded by 28% globally. Pharmaceutical-grade lentinan utilization increased by 24% due to rising interest in adjunct cancer therapies and immune-supportive treatment formulations. More than 46% of nutraceutical product launches included mushroom-derived polysaccharides for wellness applications.

Organic shiitake mushroom cultivation increased by 21% globally because clean-label ingredient demand continued expanding. Encapsulated lentinan products represented approximately 33% of immune-health supplement launches during 2024 due to improved bioavailability and dosage stability. Functional beverages containing mushroom extracts increased by 17%, especially across North America and Asia-Pacific. Powdered mushroom supplement consumption rose by 26% because consumers preferred convenient plant-based nutrition formats.

Lentinan Market Dynamics

DRIVER

"Rising demand for immune-support nutraceuticals and oncology supplements"

The growing demand for immune-health supplements and oncology-support products is the major driver of the lentinan market. More than 61% of supplement users globally purchased immunity-focused products during 2024, significantly increasing demand for mushroom-derived beta-glucans. Lentinan utilization in nutraceutical formulations expanded by 31% because consumers increasingly preferred natural immune-support compounds. Pharmaceutical companies also increased research involving lentinan for adjunct cancer therapies, with oncology-related beta-glucan studies rising by 19%. Functional food products containing shiitake mushroom extracts increased by 23% globally. More than 48% of wellness consumers preferred plant-derived polysaccharides over synthetic immune boosters. Aging populations above 65 years also contributed significantly, with nearly 27% of elderly consumers regularly using immunity supplements containing mushroom extracts.

RESTRAINT

"Limited awareness and inconsistent raw material supply"

Limited consumer awareness and unstable shiitake mushroom supply remain significant restraints within the lentinan market. Approximately 22% of consumers in emerging economies remain unfamiliar with lentinan health applications despite rising mushroom supplement popularity. Climate-related agricultural fluctuations impacted nearly 18% of shiitake mushroom harvests during 2024. More than 34% of extraction manufacturers reported inconsistent raw material availability because cultivation output varied seasonally. Processing costs for pharmaceutical-grade lentinan increased by 16% because purification and extraction procedures require advanced biotechnology infrastructure. Smaller nutraceutical firms also faced quality standard compliance issues, with approximately 21% of mushroom extract batches failing purity consistency benchmarks. Regulatory approval procedures for mushroom-derived therapeutic compounds remain lengthy in several countries, delaying product commercialization.

OPPORTUNITY

"Expansion in functional foods and pharmaceutical applications"

The expansion of functional foods and pharmaceutical applications presents major opportunities for the lentinan market. Functional food launches containing mushroom extracts increased by 27% globally during 2024. Lentinan integration into soups, beverages, protein bars, and wellness snacks improved because consumers increasingly preferred immunity-supportive diets. Pharmaceutical-grade lentinan demand expanded by 24% due to ongoing oncology research and immunotherapy support applications. More than 41% of clinical nutrition product manufacturers invested in mushroom-derived ingredients for hospital nutrition solutions. Encapsulation technologies improved beta-glucan bioavailability by 18%, supporting new supplement development opportunities. Asia-Pacific countries increased biotechnology investment by 22% to improve lentinan extraction efficiency. Organic mushroom farming areas also expanded by 19%, supporting clean-label and non-GMO product development across nutraceutical industries.

CHALLENGE

"Competition from synthetic and alternative beta-glucan ingredients"

Competition from synthetic immune compounds and alternative beta-glucan sources remains a major challenge within the lentinan market. Oat-derived beta-glucans represented approximately 29% of global immune-health ingredient utilization during 2024 because of lower production costs and stronger consumer familiarity. Synthetic immune-support additives remain widely used in pharmaceutical formulations due to standardized purity levels. More than 26% of supplement manufacturers reported switching between mushroom-derived and grain-derived beta-glucans based on pricing and supply availability. Lentinan extraction costs increased by 14% because advanced purification systems require high energy utilization and laboratory-grade filtration equipment. Consumer confusion regarding mushroom polysaccharide terminology also affected product adoption, especially across developing retail markets where awareness remains limited.

Lentinan Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Food Grade: Food-grade lentinan represented approximately 42% of the global lentinan market during 2024 because of rising demand for functional foods and dietary supplements. More than 46% of mushroom-based supplement launches included food-grade lentinan as a primary active ingredient. Functional beverages containing mushroom beta-glucans increased by 17% globally because consumers increasingly preferred immunity-supportive drinks. North America accounted for nearly 31% of food-grade lentinan consumption due to strong clean-label food demand. Powdered mushroom supplement production exceeded 148 million units during 2024. Organic food-grade lentinan products increased by 21% because health-conscious consumers preferred non-GMO and plant-derived ingredients. Food manufacturers also integrated lentinan into soups, protein bars, and wellness snacks to improve nutritional value and immune-support positioning.

Pharmaceutical Grade: Pharmaceutical-grade lentinan dominated nearly 58% of the lentinan market because oncology-related applications and immune-supportive therapies expanded significantly. More than 39% of clinical beta-glucan formulations used pharmaceutical-grade lentinan during 2024. Purified lentinan extraction facilities increased by 24% across Asia-Pacific and North America because pharmaceutical manufacturers required higher purity standards above 98%. Oncology-support applications represented approximately 43% of pharmaceutical-grade utilization. Japan and China collectively accounted for nearly 61% of pharmaceutical lentinan production because advanced mushroom biotechnology infrastructure remains concentrated in these countries. Injectable and capsule-based formulations increased by 19% due to rising hospital demand for adjunct immune-support therapies. Clinical trials involving mushroom polysaccharides also expanded by 16% during 2024.

By Application

Food Additive: Food additive applications accounted for approximately 27% of the lentinan market because functional food manufacturers increasingly incorporated mushroom-derived polysaccharides into health-oriented products. More than 18,000 food products launched globally during 2024 contained beta-glucan ingredients. Lentinan utilization in soups, ready meals, and nutritional beverages increased by 22% because immune-health positioning became a key marketing focus. Asia-Pacific represented nearly 49% of food additive demand because mushroom-based foods remain highly popular across China, Japan, and South Korea. Functional bakery products containing mushroom extracts increased by 14% during 2024. Encapsulated food additive formulations also improved ingredient stability by approximately 16%.

Health Product Field: Health product applications represented approximately 34% of the lentinan market because dietary supplements and wellness products continue witnessing strong global demand. Mushroom-based immunity supplements increased by 31% during 2024 across retail and e-commerce platforms. Capsules and powdered supplements accounted for nearly 63% of health product formulations using lentinan. North America represented approximately 36% of global health product consumption because more than 61% of adults regularly consume dietary supplements. Organic mushroom extract products increased by 19% due to rising clean-label preferences. Functional wellness blends combining lentinan with vitamins and probiotics also expanded by 17% globally.

Anti-Cancer Drug: Anti-cancer drug applications dominated approximately 39% of the lentinan market because lentinan is widely studied for immune modulation and oncology-supportive therapy. Clinical oncology studies involving mushroom beta-glucans increased by 18% during 2024. Pharmaceutical-grade injectable lentinan formulations represented nearly 41% of anti-cancer applications because hospital-based immunotherapy support treatments gained attention. Asia-Pacific accounted for approximately 58% of anti-cancer lentinan utilization because Japan and China maintain advanced mushroom-derived pharmaceutical manufacturing sectors. Hospital demand for adjunct immune-supportive therapies increased by 21% globally. More than 32% of biotechnology firms researching mushroom compounds included lentinan in oncology-focused development programs.

Lentinan Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America represented approximately 16% of the lentinan market during 2024 because dietary supplement consumption and functional food demand continued expanding rapidly. The United States accounted for nearly 84% of regional lentinan utilization due to strong nutraceutical manufacturing infrastructure. More than 61% of adults in North America regularly consumed dietary supplements, directly supporting mushroom beta-glucan demand. Pharmaceutical-grade lentinan represented approximately 44% of regional consumption because oncology-support formulations gained stronger clinical interest. Functional beverages containing mushroom extracts increased by 18% during 2024 because consumers increasingly preferred plant-based immune-support products. More than 3,400 nutraceutical companies across the region manufactured mushroom-derived capsules, powders, and tablets. Canada contributed nearly 11% of regional demand because organic supplement consumption increased by 16%. Food additive applications also expanded significantly, with wellness snack launches containing mushroom ingredients rising by 14%.

E-commerce sales of mushroom supplements increased by 27% across North America during 2024. Encapsulated lentinan products represented nearly 38% of retail mushroom supplement sales because convenient dosage formats gained popularity. Investments in mushroom biotechnology research increased by 21%, supporting clinical development of advanced beta-glucan formulations.

Europe

Europe accounted for approximately 11% of the lentinan market because clean-label supplements and plant-based wellness products continue gaining popularity. Germany, France, and the United Kingdom collectively represented nearly 57% of regional lentinan consumption during 2024. Organic mushroom supplement launches increased by 22% because consumers increasingly preferred non-synthetic immunity ingredients. Pharmaceutical applications represented approximately 36% of regional demand because hospital nutrition and adjunct oncology therapies expanded steadily.

Functional food products containing mushroom beta-glucans increased by 17% across Europe because wellness-oriented food consumption remained high. Encapsulated mushroom extract supplements accounted for nearly 41% of retail nutraceutical sales. Europe imported more than 7,600 metric tons of shiitake mushroom extracts during 2024 to support domestic supplement manufacturing. Biotechnology research involving beta-glucans increased by 15% because academic and pharmaceutical institutions focused on immune modulation studies. Food additive applications represented approximately 28% of regional lentinan demand because mushroom-derived polysaccharides were increasingly integrated into soups, beverages, and health snacks. Sustainable packaging for nutraceutical products also improved by 13%, supporting premium supplement branding strategies.

Asia-Pacific

Asia-Pacific dominated the lentinan market with approximately 68% share because the region maintains the world’s largest shiitake mushroom cultivation and extraction infrastructure. China alone contributed nearly 82% of global shiitake mushroom production during 2024, while Japan and South Korea maintained advanced mushroom biotechnology industries. Pharmaceutical-grade lentinan represented approximately 61% of regional demand because oncology-supportive applications remain widely utilized across healthcare systems. Functional food applications accounted for nearly 33% of regional consumption because mushroom-based nutrition products remain culturally established across East Asia. More than 11 million metric tons of shiitake mushrooms were produced globally during 2024, with Asia-Pacific contributing the majority of output. Encapsulated immune-health supplements increased by 29% across regional retail channels because wellness awareness continued expanding rapidly.

Japan accounted for approximately 18% of Asia-Pacific pharmaceutical lentinan utilization because clinical oncology applications remain well established. India recorded a 16% increase in mushroom nutraceutical manufacturing during 2024 due to rising dietary supplement consumption. More than 4,800 mushroom extraction facilities operated across China, Japan, and South Korea, supporting large-scale lentinan production and export activities.

Middle East & Africa

Middle East & Africa accounted for approximately 5% of the lentinan market because functional food imports and mushroom supplement consumption increased steadily during 2024. Gulf countries contributed nearly 48% of regional demand because health-conscious consumers increasingly purchased imported immune-support supplements. South Africa represented approximately 19% of regional lentinan utilization because nutraceutical retail sales expanded significantly. Dietary supplement consumption increased by 14% across urban populations during 2024. Health product applications accounted for nearly 44% of regional demand because immunity-focused wellness products remained the primary category for mushroom-derived ingredients. Functional beverage launches containing mushroom extracts increased by 11% across major metropolitan areas. Imports of shiitake mushroom extracts rose by 17% because local cultivation infrastructure remains limited in arid climates.

Pharmaceutical applications represented approximately 28% of regional lentinan consumption because hospital nutrition and adjunct immune-support formulations expanded gradually. Investments in nutraceutical retail chains increased by 13% during 2024. Online supplement sales also rose by 21% across Gulf nations, improving consumer access to premium mushroom-derived wellness products.

List of Top Lentinan Companies

• Ajinomoto
• Elicityl
• Nammex
• Panjin Gerun Biotech
• Golden Horizon Biologics
• Acetar Bio-Tech
• Johncan Mushroom Bio-technology
• Xian Changyue Phychemistry
• Xian Yuansun Biological

Top Two Companies by Market Share

• Ajinomoto held approximately 17% of the global lentinan market during 2024 because of advanced pharmaceutical-grade beta-glucan production and extensive oncology-support product distribution.
• Nammex accounted for nearly 13% market share due to strong mushroom extract supply capabilities and rising demand for organic immune-support nutraceutical ingredients.

Investment Analysis and Opportunities

The lentinan market continues attracting investments because immune-health supplements, oncology-support products, and mushroom-derived nutraceuticals remain high-growth wellness categories. Investments in mushroom biotechnology facilities increased by 23% globally during 2024. China expanded industrial shiitake cultivation areas by 19%, supporting long-term raw material availability for lentinan extraction. Pharmaceutical-grade extraction facilities also increased by 24% across Asia-Pacific due to rising demand for purified beta-glucan compounds.

Europe also presented strong investment opportunities because organic supplement demand increased by 22%. Biotechnology firms increased clinical research involving lentinan and oncology-support therapies by 16% during 2024. Online wellness retail platforms expanded mushroom supplement distribution by 27%, improving market accessibility. Sustainable mushroom cultivation projects also gained 14% higher agricultural funding due to growing consumer preference for environmentally responsible nutraceutical production systems.

New Product Development

New product development in the lentinan market focuses on bioavailability enhancement, clean-label formulations, and multifunctional wellness products. Encapsulated lentinan supplements with improved absorption efficiency increased by 26% during 2024. Powdered mushroom drink mixes containing lentinan and probiotics expanded by 18% because consumers increasingly preferred convenient immunity-support beverages. Functional gummies using mushroom beta-glucans gained 14% higher demand among younger consumers.

Cosmetic applications using mushroom beta-glucans also increased by 13% because skincare brands promoted immune-supportive and antioxidant formulations. Functional food manufacturers introduced protein bars and nutrition powders enriched with lentinan to target sports nutrition consumers. Biotechnology firms developed nano-encapsulation methods that improved lentinan absorption by approximately 19%, supporting higher efficacy in clinical and nutraceutical applications. Vegan-certified mushroom supplements also expanded by 16% because plant-based wellness products continued gaining global popularity.

Five Recent Developments (2023-2025)

• In 2023, Ajinomoto expanded pharmaceutical-grade lentinan extraction capacity by 18% to support increasing oncology-support product demand across Asia-Pacific.
• In 2024, Nammex launched organic mushroom beta-glucan capsules with polysaccharide purity exceeding 30%, targeting immune-health supplement consumers.
• In 2024, Panjin Gerun Biotech improved shiitake extraction efficiency by 16% through advanced filtration and purification technologies.
• In 2025, Golden Horizon Biologics introduced encapsulated lentinan powders with 19% higher bioavailability for nutraceutical and clinical nutrition applications.
• In 2025, Johncan Mushroom Bio-technology expanded mushroom cultivation infrastructure by 21% to strengthen raw material supply for pharmaceutical-grade lentinan manufacturing.

Report Coverage of Lentinan Market

The lentinan market report provides detailed analysis of shiitake mushroom production, beta-glucan extraction technologies, nutraceutical demand, and pharmaceutical applications across global markets. The report evaluates food-grade and pharmaceutical-grade lentinan production using verified industrial processing data and healthcare utilization trends. More than 25 countries were analyzed based on mushroom cultivation output, supplement consumption, and biotechnology infrastructure development.

Competitive analysis profiles leading manufacturers involved in mushroom extraction, purified beta-glucan production, and clinical nutrition ingredient development. The report also examines oncology-support research, encapsulation technology advancements, organic mushroom farming expansion, and clean-label wellness trends influencing future lentinan market demand. Detailed analysis of raw material supply chains, extraction efficiency, clinical applications, and nutraceutical investments provides comprehensive insights into global lentinan market developments.